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Coronary artery disease this year will claim the lives of more than 
600,000 Americans. BUSM scientist Carl Franzblau, Ph.D., has for 10 
years headed a research project that examines the role of arterial 
connective tissue components in this disease. See story on page 2. 
Shelf-life of blood 
extended through 
freeze-preservation, 
rejuvenation process 
Researchers at the Naval Blood Re-
search Laboratory at Boston Univer-
sity School of Medicine have devel-
oped methods of preserving and re-
juvenating blood cells that are ex-
pected to revolutionize the nation's 
blood-banking system. For instance, 
the researchers have developed; 
• a freeze-preservation technique 
that enables red blood cells, 
normally able to be preserved for 
a maximum of five weeks, to be 
preserved for up to 10 years; 
• methods to biochemically rejuve-
nate outdated red blood cells 
that ordinarily would be dis-
carded after liquid storage; 
• methods to boost the oxygen-
transport capability of red blood 
cells by 150 to 200 percent, to 
allow the cells to be used for 
special medical purposes. 
The procedures, the result of 
nearly 25 years of research, already 
are being put to use. The labora-
tory's techniques for freeze-
preservation of red blood cells has 
been adopted by numerous civilian 
and military blood banks throughout 
the country, including the blood bank 
at University Hospital, a principal 
teaching hospital of BUSM. More re-
cently, the rejuvenation technique 
has been adopted by the American 
Red Cross in Boston and by several 
hospitals. 
continued on page 3 
Robert Krane, M.D., left, and Mike Siroky, M.D., examine a patient's neurouroiogic test results. 
(Pfioto by Bradford F. Herzog) 
BUSM researchers advance 
treatment of male impotence 
Occasional impotence, or the failure 
to achieve and maintain an erection, 
is part of a normal sexual life. At 
some time in their lives, most males 
experience impotence due to anxiety, 
stress, guilt, depression or an excess 
of drugs or alcohol. For some males, 
though, impotence is a chronic and 
disturbing problem. Boston University 
School of Medicine researchers have 
been studying the problem for some 
time and have made important con-
tributions regarding the diagnosis 
and treatment of those having impo-
tence. 
Robert Krane, M.D., chairman of 
the School's Department of Urology, 
chief of the Department of Urology at 
University Hospital and co-director of 
the New England Male Reproductive 
Center at the Hospital, is studying 
this problem with Mike Siroky, M.D., 
also co-director of the Male 
Reproductive Center, and Terry 
Payton, R.N. Siroky also is an 
assistant professor of urology at 
BUSM. 
continued on page 5 
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Connective tissues may provide key 
to understanding atherosclerosis 
More than 600,000 Americans will 
die this year from coronary artery 
disease. The primary cause of this 
disease is atherosclerosis, which oc-
curs when the inner walls of the ar-
teries thicken and narrow, obstructing 
the blood supply to vital organs. 
What follows can be death of heart 
tissue (myocardial infarction), death 
of brain tissue (stroke, or cerebral in-
farction), or, occasionally, gangrene 
of the hands and feet. 
High blood cholesterol levels are 
believed to be responsible for much 
of the accumulation of fat that thick-
ens the inner arterial walls. This ac-
cumulation eventually leads to the 
formation of atherosclerotic plaque, 
thick, crusty material primarily con-
sisting of hardened arterial connec-
tive tissue proteins known as colla-
gen and elastin, lipids, calcium and 
phosphate. Lipids, which are fatty 
substances that make up the struc-
ture of living cells, also accumulate in 
arteries blocked with plaque. 
Carl Franzblau, Ph.D., chairman of 
Boston University School of Med-
icine's Department of Biochemistry, 
has headed a research project fo-
cused on the role that connective tis-
sue components play in ather-
osclerosis. His work, supported by 
the National Heart, Lung and Blood 
Institute, is part of a 10-year effort by 
researchers at Boston University 
Medical Center to clarify the causes 
of the disease and determine the 
best treatment. 
Arteries, the vessels that carry 
blood from the heart through the 
body, are made up of three layers of 
cells: the endothelial, or inner layer; 
the medial, or middle layer; and the 
adventitia, or outer layer. The middle 
layer primarily consists of smooth 
muscle cells that produce collagen 
and elastin. 
Collagen is an inflexible substance 
that is the main supportive protein of 
A portion of a smootfi muscle cell derived 
from a rabbit's pulmonary artery is shown 
above. This cell has been grown In a culture. 
Note the collagen outside of the cell as 
indicated. (Micrograph courtesy of Paul 
Toselli, M.D., Ph.D., and Pamela Oliver, B.S., 
BUSM Department of Biochemistry.) 
skin, tendon, bone, cartilage, and 
blood vessels. Elastin, which is brittle 
when dry, is flexible and elastic when 
moist. Together, collagen and elastin 
provide strength and flexibility be-
tween cells, much like the relation-
ship of mortar to bricks, Franzblau 
explained. 
For unknown reasons, smooth 
muscle cells sometimes over-
proliferate, resulting in the excessive 
production of collagen. As more con-
nective tissue is produced, it may 
calcify or harden, and eventually 
close, the lumen of the artery 
through which blood flows. As a re-
sult, the blood supply is severely 
hampered and the heart does not re-
ceive enough oxygen. Acute pain 
then sets in, and a myocardial infarc-
tion occurs. 
Franzblau and his team of co-
investigators have been looking for 
clues to help them better understand 
the nature of these arterial connec-
tive tissues. "It is our belief," said 
Franzblau, "that by studying the cells 
involved in atherosclerosis, we 
should gain new insights into the 
disease process. 
"We do know that atherosclerosis 
is multifactorial," Franzblau con-
tinued. "Lipids, lipoproteins, calcium 
and glycoproteins, as well as the 
connective tissue proteins, collagen 
and elastin, are all components in 
the final debilitating plaque that forms 
the latter stages of the disease." 
But what triggers abnormal prolif-
eration of smooth muscle cells in the 
arteries? How can these events be 
monitored? Are there any inherent 
protections against atherosclerosis? 
To answer these and many other 
questions about arterial connective 
tissue in vivo, Franzblau and his 
group have developed cultures of 
arterial smooth muscle cells that are 
capable of producing large quantities 
of connective tissue proteins. The 
cultures, which are derived from the 
artery of a young rabbit or calf, are 
fed several nutritive substances. The 
cells, grown in sterile dishes, multiply 
continuously and accumulate. 
Biochemists at the School of 
Medicine, who conduct the bulk of 
their work in the School's Housman 
Medical Research Center, also have 
been evaluating the role of estrogen 
in the formation of connective tissue 
proteins. 
Gail Sonenshein, Ph.D., an assis-
tant professor of biochemistry and an 
Established Investigator of the Amer-
ican Heart Association, has been re-
searching the effects of estradiol, the 
major human female hormone, on a 
smooth cell culture system. 
"Using two culture systems — one 
fed estrogens and one not — we 
study the regulation of the events in-
volved in the production of collagen," 
she explained. "What we have ob-
served is that after estrogen is intro-
duced into the system, collagen 
production decreases." 
To fully understand how these 
events are regulated, Sonenshein 
dissects cells to examine their nuclei 
and to observe what happens to the 
hereditary factors, chromosomes and 
genes. Here the messenger 
molecules that carry the coded ge-
netic information are produced and 
travel to the cytoplasm. It is in the 
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Carl Franzblau, Ph.D., instructs a biochemistry 
class at the School of Medicine. (Photo by 
Bradford F. Herzog) 
cytoplasm, or the outer portion of the 
cell, where proteins are produced. 
"Further research and evaluation in 
this area may help us gain insight 
into the prevention or regression of 
atherosclerosis, and whether other 
types of hormones affect the cells," 
Sonenshein said. "In the future, we 
will use cloning technology with re-
combinant DNA molecules." 
Franzblau emphasized the col-
laborative nature of the research in 
atherosclerosis taking place at the 
Medical Center. "We don't operate in 
a vacuum," he said. "We have had a 
long-term collaboration with William 
Hollander, M.D., a BUSM professor 
of medicine, physiology and 
biochemistry, who is the principal in-
vestigator of a large research pro-
gram in atherosclerosis." 
Working with members of the Car-
diovascular Institute at BUSM, 
Franzblau has been able to simulate 
hypertension in the laboratory. Cells 
are placed in a newly-designed 
pressure machine that mimics a 
hypertensive environment. By simu-
lating an in vivo act, Franzblau ex-
plained, one can closely monitor and 
evaluate the effects on the cells. 
Franzblau and other members of the 
Department of Biochemistry also plan 
to develop an aging smooth cell cul-
ture system to study the effects, if 
any, of aging on the pathogenesis of 
atherosclerosis. 
"Although there are inherent 
shortcomings in all cell culture sys-
tems when one tries to relate the 
data to the in vivo situation, we are 
optimistic that new insights into our 
understanding of the development of 
atherosclerosis will be forthcoming," 
Franzblau concluded. 
Other members of the BUSM De-
partment of Biochemistry who are in-
vestigators in the connective tissue 
and smooth muscle cell research 
project, along with Franzblau and 
Sonenshein, are Lily Salcedo, M.D., 
Ph.D., and Paul Toselli, M.D., Ph.D., 
both assistant professors of 
biochemistry, and John Beldekas, 
Ph.D., a research associate in the 
Department. Graduate students and 
postdoctoral fellows also contribute 
significantly. 
Herbert M. Kagan, Ph.D., and Karl 
Schmid, Ph.D., both professors of 
biochemistry, are investigating other 
aspects of the development of 
atherosclerosis. 
—Susan B. Saperstein 
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Blood preservation . . . 
continued from page 1 
"We are involved in areas of blood 
research that have dramatically im-
proved the blood-banking system in 
both the military and civilian com-
munity, " said Capt. 0. Robert Valeri, 
MO, USN, an adjunct research pro-
fessor of medicine at BUSM, who 
has served as director of the NBRL 
since 1963. 
Charles P. Emerson, M.D., an 
emeritus professor of medicine at 
BUSM, is principal investigator for 
the facility, which provides a vital link 
for those doing blood research at 
numerous medical schools and hos-
pitals in the Boston area. Others 
doing research at the NBRL include 
Eugene N. Serrallach, Ph.D., a re-
search associate in medicine at 
BUSM; Richard Dennis, M.D., an as-
sistant visiting surgeon at University 
Hospital; and Cmdrs. Anthony J. 
Melaragno, MC, USN, and Allen Nor-
land, MO, USNR, and Lt. Craig 
Thompson, MC, USNR. 
The history of the NBRL, interna-
tionally known for its research on the 
preservation of blood and blood 
products, dates back to 1956 when 
the laboratory was part of Chelsea 
Naval Hospital in Boston. It was es-
tablished as a separate unit of the 
hospital in 1965 by the Navy's Bu-
reau of Medicine and Surgery, and it 
remained at the hospital until the in-
stallation was closed in 1976. The 
laboratory then moved to temporary 
quarters in BUMC's Talbot Building 
pending renovation of its present site 
on Albany Street, adjacent to the 
Medical Center. The building on Al-
bany Street was donated to Boston 
University by New England Nuclear 
Corporation. The Medical Center, in 
turn, deeded the building to the Navy 
for its frozen blood program. The 
government-owned laboratory has 
been administered by the University 
under an Office of Naval Research 
contract since 1979. 
Researchers at the laboratory. 
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supported by the Bureau of Medicine 
and Surgery's Naval Medical Re-
search and Development Command, 
since 1956 have been developing 
ways in which the shelf-life of blood 
and its components can be ex-
tended. Working with blood from 
animals and humans, the research-
ers have devised a system in which 
a universal blood type, such as 0 + 
or can be biochemically modified 
(rejuvenated), frozen with the cryo-
/protectant, glycerol, then stored at 
-80°C, nearly triple the coldness of 
a home freezer, for transfusion at a 
later date when the red cells may be 
unavailable through the regular 
blood-banking system. 
The entire process takes place in a 
routine polyvinylchloride plastic bag 
that was designed by the NBRL re-
searchers to simplify the process and 
to ensure that the red blood cells 
would not become contaminated dur-
ing the rejuvenation and freezing 
procedures. 
When needed, the frozen red cells 
are thawed in a warm water bath and 
then washed to remove the rejuvena-
tion and glycerol solutions before 
being transfused into a patient. 
Among the researchers' findings 
are that nonrejuvenated frozen red 
cells (red cells frozen within three to 
six days of collection) can be stored 
at -80°C for at least 10 years. They 
also have found that indated and 
outdated-rejuvenated red cells can 
be frozen for up to four years at 
- 8 0 C. 
In addition to preserving the red 
cell component of blood, the 
researchers are striving to improve 
the preservation of platelets and 
plasma-clotting proteins that are in-
volved in blood clotting; white cells 
that help the body fight infection and 
disease; lymphocytes that play a key 
role in the body's immune system; 
and hemopoietic stem cells that pro-
duce red and white blood cells and 
platelets. 
"With further research, we expect 
to be able to expand the present 
period during which platelets can be 
frozen and stored at minus 80 de-
A unit of red cells is prepared for freezing at the Naval Blood Research Laboratory. The 
process takes place in a plastic bag designed by the researchers to simplify the process and 
ensure that the cells would not become contaminated during the procedures. (Photo courtesy 
of the Naval Blood Research Laboratory.) 
grees Centigrade by at least two 
years with a solution of dimethylsul-
foxide," Valeri said. 
"It has been almost 25 years since 
freeze-preservation technology was 
first instituted as a means to supple-
ment the liquid blood-banking sys-
tem. During this time, freeze-
preserved red blood cells have been 
used to supply rare red cells; red 
cells lacking antigens that commonly 
sensitize recipients; the donor's own 
red cells for anticipated future use; 
and red cells free of white cells, 
platelets and plasma proteins to pre-
vent transfusion reactions," Valeri 
said. 
The researchers also found that 
red blood cells, though viable for 
several weeks in the liquid state, do 
not transport oxygen normally after 
the first week. They developed 
methods to prepare and preserve red 
cells with a normal or improved oxy-
gen delivery capacity by using 
biochemical modification and preser-
vation in the frozen state for at least 
four years. 
"Red cells with super-normal (150 
to 200 percent of normal) oxygen 
transport function have been used to 
treat hypothermic patients in hemor-
rhagic shock, patients with fixed 
cerebral or coronary blood flow, and 
patients undergoing extracorporeal 
circulation," Valeri said. 
—Marge Dwyer 
Suggested Further Readings 
1. Valeri, C.R. et al: Freezing in the primary 
polyvinylchloride plastic collection bag: a 
new system for preparing and freezing non-
rejuvenated and rejuvenated red blood cells. 
Transfusion 21: 138, 1981. 
2. Valeri, C.R.: Blood banking and the use of 
frozen blood products. Chemical Rubber 
Company, Boca Raton, Fla., 1976. 
3. Valeri, C.R. and Altschule, M.D.: 
Hypovolemic anemia of trauma: the missing 
blood syndrome. Chemical Rubber Com-
pany, Boca Raton, Fla., 1981. 
4. Valeri, C.R.: The current state of platelet 
and granu locyte cryopreservation. Crit Rev 
Clin Lab Sci. In press. 
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Male impotence . . . 
continued from page 1 
"Short-term situational impotence 
is quite common," said Krane, "but 
doctors are discovering more and 
more men whose problem is not 
psychological in nature, as was long 
believed, but has physical origins." 
This awareness is helping doctors 
find new approaches to treatment. 
Doctors have long known that an 
erection is controlled by stimulation 
of the nerves of the parasympathetic 
nervous system (one of the two divi-
sions of the automatic nervous sys-
tem that regulates such "automatic" 
activities as heart action). "We have 
found, however, that the sympathetic 
nervous system is also involved and 
we are attempting to prove this by 
studying the effects of drugs on the 
neurophysiology of erection in the 
dog," Krane said. "We know that cer-
tain drugs, such as those taken for 
high blood pressure, may interfere or 
block nerve receptors and lead to 
impotence. One goal of this research 
is to elucidate the neurophysiology of 
impotence and to develop drugs that 
could treat this problem." 
In addition to certain drugs, such 
as those that lower blood pressure, 
anti-depressants, sleeping pills, tran-
quilizers, and alcohol, there are 
many other physical causes of impo-
tence. Diabetes, for instance, can 
cause penile atherosclerosis and im-
pede blood flow to the erectile tis-
sues, resulting in impotence. Other 
causes are paraplegia, structural ab-
normalities and injuries to the geni-
tals, surgery for cancers of the pelvic 
area, Peyronie's disease (accumula-
tion of scar-like tissue in the penis), 
and malnutrition. Hypertension and 
smoking may also be risk factors, as 
they narrow the arteries, restricting 
blood flow to the penis. 
"These physical causes account 
for 48 percent of impotence cases, 
with the remaining 52 percent due to 
psychological causes. Of the physical 
causes," explained Krane, "21 per-
cent are due to vascular problems in 
which blood flow to the penis is insuf-
ficient to permit erection, 19 percent 
are neurological conditions due to 
diseases or nerve injury, and 8 per-
cent are endocrinological, due to ab-
normal amounts of hormone. 
"It appears that impotence of 'old 
age' is actually due to vascular 
causes," said Krane, "but vascular 
insufficiency can also affect relatively 
young men, say men in their forties. 
Studies by Kinsey (the famous re-
searcher on sexuality), seemed to 
show that with each decade of age, 
there are marked increases in the 
rate of impotence, but age is not 
necessarily the cause." Some loss of 
potency may occur with advancing 
age, but in a healthy male, the ca-
pacity for an erection should persist 
well into the seventies. 
Clinical research by Krane and 
Siroky has lead to the development 
of a test to diagnose vasculogenic 
impotence. An erection occurs when 
blood fills the corpora — the two 
rod-shape bundles of spongy tissue 
that constitute most of the penis. 
When blood flow to the penis is im-
peded due to such things as pelvic 
surgery, arterial disease, injury, or 
structural abnormality, impotence re-
sults. "By measuring blood pressure 
in the corpora before and after leg 
exercise, we can detect abnor-
malities and obstructions of the 
penile arteries," Krane said. "Thus, 
penile blood pressure should be 
monitored routinely." This can be 
done with a special blood pressure 
cuff fitted to the penis and a Doppler 
probe, an instrument that reflects ul-
trasound waves from blood circulat-
ing in the penile arteries. 
"One possible solution to ob-
structed penile arteries is angiodila-
tion, or stretching the artery at the 
point of obstruction, thereby letting 
the blood flow more freely to the 
penis," said Krane. 
Lack of sufficient blood to the 
penile arteries may be due to a 
mechanism in the body that diverts 
blood from the penis to the legs in 
what is called "pelvic steal." "We've 
observed many patients who were 
able to obtain erections while lying 
on their backs, but lost them when 
they moved their thigh or buttock 
muscles," Krane said. 
Krane and Siroky are also using 
x-rays to observe any changes that 
may have occurred in the arteries, 
and to see whether or not the ar-
teries are normal. A contrast media 
is injected into the arteries that sup-
ply the penis, thereby enabling the 
researchers to observe these 
changes. 
Other vasculogenic research in-
volves studying the mechanism of 
impotence after therapeutic radiation. 
Radiation for pelvic tumors often 
leads to impotence. "By the use of 
radionucleic scanning techniques, we 
may be able to diagnose vas-
culogenic impotence. Hopefully, 
these radiation studies will lead to 
better use of radiation to prevent the 
occurrence of impotence," Krane 
said. 
Future research will involve study-
ing the role of kidney failure and 
anti-hypertension medication. "Both 
of these cause impotence, and by 
neurological testing and use of the 
Doppler probe, we hope to under-
stand the mechanism by which they 
cause impotence," Krane said. 
"Besides being due to vascular 
problems, impotence also may be 
caused by hormonal abnormalities 
more often than previously believed," 
Krane said. In the past, men with im-
potence were told to see a psychia-
trist, but due to recent advances in 
endocrinology, doctors are restructur-
ing their approach. Krane and 
Siroky's research in this area in-
volves testing the levels of hormones 
that are associated with impotence 
— testosterone, prolactin, and es-
tradiol. "In a recent study of 260 pa-
tients, 21 were found to have low 
testosterone levels," he said. 
In addition, an excessive amount 
of prolactin, produced by the pituitary 
gland, may interfere with erection. 
"We are studying specific treatments 
with new drugs and treating some 
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cases with appropriate hormones," 
said Krane. 
If sex therapy, vascular surgery or 
hormonal treatment fail to restore po-
tency, one last remedy is a penile 
implant, an artificial device that pro-
duces an erection. The School of 
Medicine researchers were the first 
in the United States to implant a new 
prosthetic device designed by Udo 
Jonas, a German physician. In fact, 
Krane and Siroky evaluated the 
Jonas implant for Food and Drug 
Administration approval. 
The Jonas implant consists of a 
pair of flexible cylinders made of 
silicone rubber surrounding an inner 
core of silver wire. Because of the 
flexibility of the silver core, the penis 
may be positioned manually in either 
a resting state or at an erect angle. 
Implantation, which takes about 30 
minutes, involves placing one rod in 
each corpora. "We've had an excel-
lent success rate with the Jonas," 
said Krane. "Out of the first 73 we 
implanted, there were only five com-
plications, which resulted in removing 
three; the rest are functioning well." 
Another device that Krane and 
Siroky implant is "the pump" or an 
inflatable prosthesis. This involves 
inserting two expandable, balloon-
type cylinders into the corpora. The 
cylinders are connected by tubing to 
a small reservoir implanted near the 
bladder, and to a tiny pump, inserted 
in the scrotum. When squeezed, the 
pump forces saline solution from the 
reservoir into the cylinders in the 
penis, resulting in an erection. After 
ejaculation, the pump's release valve 
can be opened, causing the solution 
to flow back into the reservoir. 
The inflatable pump, an implant device 
used In the treatment of male 
impotence. Is shown above in detail. 
When the pump is squeezed, solution 
flows from the reservoir Into the 
cylinders, resulting in an erection. After 
ejaculation, the solution flows back into 
the reservoir. (Diagram by JoEllen 
Murphy, Educational Media, BUSM) 
Patients who receive implants 
come to the Medical Center from all 
over New England. Most patients are 
between the ages of 40 and 60, with 
the majority between 50 and 59. 
Very few are under age 30, unless 
they've had some kind of injury. "Not 
everyone can be helped; for exam-
ple, those incapable of orgasm. 
Those whose problem is psychologi-
cal require sex therapy. For those 
patients who have received a penile 
implant, restoration of their potency 
results in increased self-esteem. In 
fact, 65 to 75 percent of our patients 
report a greatly improved self-
image," Krane said. 
To further aid impotent patients, 
Krane and Siroky have produced a 
medical teaching film for physicians 
who implant the Jonas device, and 
they have written two books for the 
profession. The first. Clinical 
Neurouroiogy, was published by Lit-
tle Brown and Company in October, 
1979, and the second, Male Sexual 
Dysfunction, also to be published by 
Little Brown, will be out next year. 
— Liza Hubbard 
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